Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Boehringer, TARGET Pharma in Strategic NASH Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Boehringer, TARGET Pharma in Strategic NASH Pact

Observational study to incorporate TARGET model of community of stakeholders

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Boehringer Ingelheim has entered into a multi-year strategic partnership with TARGET PharmaSolutions, a real-world clinical data company, for an observational study TARGET-NASH.

This study is evaluating patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) and has enrolled 2,423 patients at 55 sites, with the expectation to enroll as many as 15,000 patients over the coming years.

The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, investigators, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes.

Meg Powell, chief executive officer of TARGET PharmaSolutions, said, “We are very excited to have Boehringer Ingelheim join TARGET-NASH as an industry partner.  We have exceeded our enrollment targets to date, and we are providing valuable real-world data and insight on NASH patients that will have a significant impact on the scientific understanding of the natural history and treatment modalities for NASH.  This data, combined with the TARGET-NASH biorepository and patient reported outcomes, will enable our collaborators to continue to increase their understanding of this growing disease.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics